Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
2.280
+0.060 (2.70%)
At close: May 29, 2025, 4:00 PM
2.290
+0.010 (0.44%)
After-hours: May 29, 2025, 6:38 PM EDT
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Aldeyra Therapeutics stock ranges from a low of $9.00 to a high of $10. The average analyst price target of $9.50 forecasts a 316.67% increase in the stock price over the next year.
Price Target: $9.50 (+316.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aldeyra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 2 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +338.60% | May 19, 2025 |
| BTIG | BTIG | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +294.74% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +338.60% | Apr 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +338.60% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +338.60% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
n/a
from 175.91M
Revenue Next Year
n/a
EPS This Year
-0.80
from -0.94
EPS Next Year
-0.70
from -0.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 179.5M | 144.4M | 138.4M | ||
| Avg | 30.9M | 56.1M | 98.8M | ||
| Low | -9.8M | 12.7M | 49.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.0% | 367.4% | 146.5% | ||
| Avg | -82.4% | 81.7% | 76.0% | ||
| Low | - | -58.8% | -11.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.62 | -0.46 | 0.14 | ||
| Avg | -0.80 | -0.70 | 0.11 | ||
| Low | -1.29 | -1.06 | 0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.